Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy
NCT ID: NCT04200989
Last Updated: 2022-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2021-03-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Peanut Immunotherapy
NCT01324401
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
NCT00932282
The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy
NCT01897077
Oral Immunotherapy (OIT) for Peanut Allergy
NCT00815035
Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults
NCT01274429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following the three ILIT peanut injections a repeat blinded oral peanut challenge is performed.
Blood is drawn at each of the 5 study visits for a variety of tests trying to elucidate the mechanism(s) of the induction of tolerance to peanut.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Peanut ILIT
Peanut allergen
Intralymphatic immunotherapy injections.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peanut allergen
Intralymphatic immunotherapy injections.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-
Exclusion Criteria
* life threatening anaphylaxis to peanut Uncontrolled asthma
15 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Scripps Research Institute
OTHER
Scripps Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ronald A Simon
Emeritus Head, Division of Asthma, Allergy and Immunology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simon A Ronald, MD
Role: PRINCIPAL_INVESTIGATOR
Scripps Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scripps Clinic
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hothorn LA, Gronlund H, Tivig C, Zaleska A, Soyer O, van Hage M, Akdis CA, Akdis M, Rose H, Kundig TM. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012 May;129(5):1290-6. doi: 10.1016/j.jaci.2012.02.026. Epub 2012 Mar 30.
Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013 Feb;131(2):412-20. doi: 10.1016/j.jaci.2012.10.056.
Lee SP, Choi SJ, Joe E, Lee SM, Lee MW, Shim JW, Kim YJ, Kyung SY, Park JW, Jeong SH, Jung JH. A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies. Allergy Asthma Immunol Res. 2017 May;9(3):272-277. doi: 10.4168/aair.2017.9.3.272.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-19-7380
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.